Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Humacyte
company
About
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $175M
- Industries
- Biotechnology,Medical,Medical Device
- Founded date
- Jan 1, 2004
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$175M
Humacyte has raised a total of
$175M
in funding over 2 rounds. Their latest funding was raised on
Aug 27, 2021 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 27, 2021 | Post-IPO Equity | $175M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Humacyte is funded by 1 investors.
UBS O'Connor
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
UBS O'Connor
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
